Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 1, 2007 - Issue 1
Submit an article Journal homepage
232
Views
15
CrossRef citations to date
0
Altmetric
Review

Familial pancreatic cancer: from genes to improved patient care

Ralph H Hruban Departments of Pathology and Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Hospital, Weinberg Building 2242, 401 North Broadway, Baltimore, MD 21231,USA. [email protected]
,
Alison P Klein Departments of Pathology and Oncology, The Sol Goldman Pancreatic Cancer Research Center, 1550 Orleans Street, Room 303, Baltimore, MD 21231, USA. [email protected]
,
James R Eshleman Departments of Pathology and Oncology, The Sol Goldman Pancreatic Cancer Research Center, 1550 Orleans Street, Room 344, Baltimore, MD 21231, USA. [email protected]
,
Jennifer E Axilbund Research Associate, Department of Oncology, 600 North Wolfe Street, 550 Building, Suite 410, Baltimore, MD 21287, USA. [email protected]
&
Michael Goggins Departments of Pathology, Oncology and Medicine, The Sol Goldman Pancreatic Cancer Research Center, 1550 Orleans Street, Room 342, Baltimore, MD 21231, USA. [email protected]
Pages 81-88 | Published online: 10 Jan 2014

References

  • American Cancer Society. Cancer facts and figures 2007. Cancer, American Cancer Society, NY, USA 1–52 (2007).
  • Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer94(2), 153–156 (2001).
  • Klein AP, Hruban RH, Brune KA, Petersen GM, Goggins M. Familial pancreatic cancer. Cancer J.7(4), 266–273 (2001).
  • Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control11(10), 915–923 (2000).
  • Falk RT, Pickle LW, Fontham ET, Correa P, Fraumeni JF. Life-style risk factors for pancreatic cancer in Louisana: a case–control study. Am. J. Epidemiol.128(2), 324–336 (1988).
  • Fernandez E, La Vecchia C, D’Avanzo B, Negri E, Franceschi S. Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol. Biomarkers Prev.3, 209–212 (1994).
  • Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C. Reported family aggregation of pancreatic cancer within a population-based case–control study in the Francophone community in Montreal, Canada. Int. J. Pancreatol.10, 183–196 (1991).
  • Ghadirian P, Liu G, Gallinger S et al. Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas. Int. J. Cancer97(6), 807–810 (2002).
  • Amundadottir LT, Thorvaldsson S, Gudbjartsson DF et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med.1(3), e65 (2004).
  • Klein AP, Brune KA, Petersen GM et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res.64(7), 2634–2638 (2004).
  • Klein AP, Beaty TH, Bailey-Wilson JE, Brune KA, Hruban RH, Petersen GM. Evidence for a major gene influencing risk of pancreatic cancer. Genet. Epidemiol.23(2), 133–149 (2002).
  • Pogue-Geile KL, Chen R, Bronner MP et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med.3(12), e516 (2006).
  • Berman DB, Costalas J, Schultz DC, Grana G, Daly M, Godwin AK. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res.56, 3409–3414 (1996).
  • Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J. Natl Cancer Inst.91(15), 1310–1316 (1999).
  • Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res.56, 5360–5364 (1996).
  • Hahn SA, Greenhalf B, Ellis I et al.BRCA2 germline mutations in familial pancreatic carcinoma. J. Natl Cancer Inst.95(3), 214–221 (2003).
  • Lal G, Liu G, Schmocker B et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res.60, 409–416 (2000).
  • Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J. Clin. Oncol.22(4), 735–742 (2004).
  • Murphy KM, Brune KA, Griffin CA et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res.62(13), 3789–3793 (2002).
  • Ozcelik H, Schmocker B, DiNicola N et al. Germline BRCA26174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat. Genet.16, 17–18 (1997).
  • Thorlacius S, Olafsdottir GH, Tryggvadottir L et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat. Genet.13, 117–119 (1996).
  • Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat. Genet.14(2), 185–187 (1996).
  • Hruban RH, Pitman MB, Klimstra DS. Atlas of Tumor Pathology. Tumors of the pancreas. Fourth Series ed. Washington, DC: Armed Forces Institute of Pathology (2007).
  • van der Heijden MS, Yeo CJ, Hruban RH, Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res.63(10), 2585–2588 (2003).
  • Couch FJ, Johnson MR, Rabe K et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res.65(2), 383–386 (2005).
  • van der Heijden MS, Brody JR, Gallmeier E et al. Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am. J. Pathol.165(2), 651–657 (2004).
  • Rogers CD, van der Heijden MS, Brune KA et al. The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol. Ther.3(2), (2004).
  • Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J. Natl Cancer Inst.94(18), 1358–1365 (2002).
  • Lynch HT, Deters CA, Snyder CL et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet. Cytogenet.158(2), 119–125 (2005).
  • Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J. Natl Cancer Inst.94(18), 1358–1365 (2002).
  • Caldas C, Hahn SA, da Costa LT et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet.8, 27–32 (1994).
  • Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res.57, 2140–2143 (1997).
  • Bartsch DK, Sina-Frey M, Lang S et al.CDKN2A germline mutations in familial pancreatic cancer. Ann. Surg.236(6), 730–737 (2002).
  • Bergman W, Watson P, de Jong J, Lynch HT, Fusaro RM. Systemic cancer and the FAMMM syndrome. Br. J. Cancer61, 932–936 (1990).
  • Borg A, Sandberg T, Nilsson K et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J. Natl Cancer Inst.92(15), 1260–1266 (2000).
  • de vos tot Nederveen Cappel WH, Offerhaus GJ, van Puijenbroek M et al. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden). Clin. Cancer Res.9(10 Pt 1), 3598–3605 (2003).
  • Goldstein AM, Fraser MC, Struewing JP et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N. Engl. J. Med.333(15), 970–974 (1995).
  • Lynch HT, Brand RE, Hogg D et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer94(1), 84–96 (2002).
  • Parker JF, Florell SR, Alexander A, DiSario JA, Shami PJ, Leachman SA. Pancreatic carcinoma surveillance in patients with familial melanoma. Arch. Dermatol.139(8), 1019–1025 (2003).
  • Vasen HF, Gruis NA, Frants RR, van der Velden PA, Hille ET, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int. J. Cancer87(6), 809–811 (2000).
  • Goldstein AM, Chan M, Harland M et al. High-risk melanoma susceptibility genes and pancreatic cancer, neuralsystem tumors, and uveal melanoma across GenoMEL. Cancer Res.66(20), 9818–9828 (2006).
  • Lynch HT, Brand RE, Lynch JF et al. Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families. Gastroenterology119(6), 1756–1760 (2000).
  • Hemminki A, Markie D, Tomlinson I et al. A serine/threonine kinase gene defective in Peutz–Jeghers syndrome. Nature391, 184–187 (1998).
  • Jeghers H, McKusick VA, Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits. N. Engl. J. Med.241(25), 992–1005 (1949).
  • Giardiello FM, Welsh SB, Hamilton SR et al. Increased risk of cancer in the Peutz–Jeghers syndrome. N. Engl. J. Med.316(24), 1511–1514 (1987).
  • Giardiello FM, Brensinger JD, Tersmette AC et al. Very high risk of cancer in familial Peutz–Jeghers Syndrome. Gastroenterology119, 1447–1453 (2000).
  • Su GH, Hruban RH, Bova GS et al. Germline and somatic mutations of the STK11/LKB1 Peutz–Jeghers gene in pancreatic and biliary cancers. Am. J. Pathol.154(6), 1835–1840 (1999).
  • Bowlby LS. Pancreatic adenocarcinoma in an adolescent male with Peutz–Jeghers syndrome. Hum. Pathol.17, 97–99 (1986).
  • Sato N, Rosty C, Jansen M, Fukushima N, Ueki T, Yeo CJ et al. STK11/LKB1 Peutz–Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am. J. Pathol.159(6), 2017–2022 (2001).
  • Whitcomb DC. Hereditary pancreatitis: new insights into acute and chronic pancreatitis. Gut45(3), 317–322 (1999).
  • Gorry MC, Gabbaizedeh D, Furey W et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology113(4), 1063–1068 (1997).
  • Finch MD, Howes N, Ellis I et al. Hereditary pancreatitis and familial pancreatic cancer. Digestion58(6), 564–569 (1997).
  • Lowenfels AB, Maisonneuve EP, Dimagno YE et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J. Natl Cancer Inst.89(6), 442–446 (1997).
  • Lynch HT, Voorhees GJ, Lanspa SJ, McGreevy PS, Lynch J. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br. J. Cancer52, 271–273 (1985).
  • Liu B, Nicolaides NC, Markowitz S et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat. Genet.9, 49–55 (1995).
  • Goggins M, Offerhaus GJ, Hilgers W et al. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am. J. Pathol.152, 1501–1507 (1998).
  • Yamamoto H, Itoh F, Nakamura H et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res.61(7), 3139–3144 (2001).
  • Wilentz RE, Goggins M, Redston M et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am. J. Pathol.156(5), 1641–1651 (2000).
  • Nakata B, Wang YQ, Yashiro M et al. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin. Cancer Res.8(8), 2536–2540 (2002).
  • Warusavitarne J, Schnitzler M. The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int. J. Colorectal. Dis. (2006).
  • Meckler KA, Brentnall TA, Haggitt RC et al. Familial fibrocystic pancreatic atrophy with endocrine cell hyperplasia and pancreatic carcinoma. Am. J. Surg. Pathol.25(8), 1047–1053 (2001).
  • Slater E, Amrillaeva V, Fendrich V et al. Palladin mutation causes familial pancreati cancer: absence in European families. PLoS Med.4(4), E164 (2007).
  • Zogopoulos G, Rothenmund H, Eppel A et al. The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Hum. Genet.121(5), 635–637 (2007).
  • Klein AP, de Andrade M, Hruban RH et al. Linkage analysis of chromosome 4 in families with familial pancreatic cancer. 6(3), 320–3. Cancer Biol. Ther. (2007).
  • Salaria SN, Illei P, Sharma R et al. Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells. Cancer Biol. Ther.6(3), 324–328 (2007).
  • Giardiello FM, Offerhaus GJ, Lee DH et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut34, 1394–1396 (1993).
  • Petersen GM, de Andrade M, Goggins M et al. Pancreatic Cancer Genetic Epidemiology (PACGENE) Consortium. Cancer Epidemiol Biomarkers Prev.15(4), 704–710 (2006).
  • Lucito R, Suresh S, Walter K et al. Copy-number variants in patients with a strong family history of pancreatic cancer. Cancer Biol. Ther.6(10) (2007) (In press).
  • Agata S, Dalla PM, Callegaro M et al. Large genomic deletions inactivate the BRCA2 gene in breast cancer families. J. Med. Genet.42(10), e64 (2005).
  • Hogervorst FB, Nederlof PM, Gille JJ et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res.63(7), 1449–1453 (2003).
  • Renkonen ET, Nieminen P, Abdel-Rahman WM et al. Adenomatous polyposis families that screen APC mutation-negative by conventional methods are genetically heterogeneous. J. Clin. Oncol.23(24), 5651–5659 (2005).
  • Casey G, Lindor NM, Papadopoulos N et al. Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer. JAMA293(7), 799–809 (2005).
  • McWhinney SR, Pilarski RT, Forrester SR et al. Large germline deletions of mitochondrial complex II subunits SDHB and SDHD in hereditary paraganglioma. J. Clin. Endocrinol. Metab.89(11), 5694–5699 (2004).
  • Hemminki K, Jiang Y. Cancer risks among long-standing spouses. Br. J. Cancer86(11), 1737–1740 (2002).
  • Schenk M, Schwartz AG, O’Neal E et al. Familial risk of pancreatic cancer. J. Natl Cancer Inst.93(8), 640–644 (2001).
  • Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology124(5), 1292–1299 (2003).
  • Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost–effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointestinal Endoscopy57(1), 23–29 (2003).
  • Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review (1973–1997). National Cancer Institute (1997).
  • Canto MI, Goggins M, Hruban RH et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin. Gastroenterol. Hepatol.4(6), 766–781 (2006).
  • Canto MI, Goggins M, Yeo CJ et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin. Gastroenterol. Hepatol.2(7), 606–621 (2004).
  • Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann. Intern. Med.131(4), 247–255 (1999).

Websites

  • Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Databases: Incidence - SEER 11 Regs + AK Public-Use, Nov 2003 Sub for Expanded Races (1992–2001) and Incidence - SEER 11 Regs Public-Use, Nov 2003 Sub for Hispanics (1992–2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission. (2004) http://seer.cancer.gov/
  • Johns Hopkins Medicine. The Sol Goldman Pancreatic Cancer Research Center http://pathology.jhu.edu/pancreas
  • University Hospital Giessen and Marburg. www.med.uni-marburg.de/e-einrichtungen/fapaca/
  • Gene tests www.genetests.org/
  • Medline Plus, Genetic testing www.nlm.nih.gov/medlineplus/genetictesting.html
  • National Society for Genetic Councelors www.nsgc.org/
  • Johns Hopkins, Pancreas cancer website http://pathology.jhu.edu/pancreas/PartNFPTR.php

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.